SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Biotech Valuation
CRSP 51.59-1.1%Dec 2 3:59 PM EST
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: John Metcalf who wrote (1661)9/17/2000 11:51:22 PM
From: aknahow  Read Replies (1) of 52153
 
<<<I don't see the possibility of a biotech that will own something indispensable to other companies, as INTC
and MSFT have done. Companies like PDLI and ABGX own technologies indispensable to some, but
don't have a hammerlock on MaB technology.>>>

While I realize this will be greeted with great laughter and scorn, just for the record, I think BPI and LBP and the peptide versions will become indispensable to others, in many areas, too numerous to mention.

Baxter/Xoma and AGN control recombinant BPI and XOMA controls peptide forms of BPI and LPB.

Disclosure.
Currently very long XOMA. At any time may write options on BAX.
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News